Literature DB >> 17189402

Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.

Chris A Learn1, Peter E Fecci, Robert J Schmittling, Weihua Xie, Isaac Karikari, Duane A Mitchell, Gary E Archer, ZhengZheng Wei, Holly Dressman, John H Sampson.   

Abstract

PURPOSE: Analyses of T-cell mRNA expression profiles in glioblastoma multiforme has not been previously reported but may help to define and characterize the immunosuppressed phenotype in patients with this type of cancer. EXPERIMENTAL
DESIGN: We did microarray studies that have shown significant and fundamental differences in the expression profiles of CD4(+) and CD8(+) T cells and immunosuppressive CD4(+)CD25(+)CD45RO(+)FoxP3(+) regulatory T cells (T(reg)) from normal healthy volunteers compared with patients with newly diagnosed glioblastoma multiforme. For these investigations, we isolated total RNA from enriched CD4(+) and CD8(+) T cell or T(reg) cell populations from age-matched individuals and did microarray analyses.
RESULTS: ANOVA and principal components analysis show that the various T cell compartments exhibit consistently similar mRNA expression profiles among individuals within either healthy or brain tumor groups but reflect significant differences between these groups. Compared with healthy volunteers, CD4(+) and CD8(+) T cells from patients with glioblastoma multiforme display coordinate down-regulation of genes involved in T cell receptor ligation, activation, and intracellular signaling. In contrast, T(regs) from patients with glioblastoma multiforme exhibit increased levels of transcripts involved in inhibiting host immunity.
CONCLUSION: Our findings support the notion that key differences between expression profiles in T-cell populations from patients with glioblastoma multiforme results from differential expression of the immunologic transcriptome, such that a limited number of genes are principally important in producing the dysregulated T-cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17189402     DOI: 10.1158/1078-0432.CCR-06-1727

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Authors:  Isaac Yang; Tarik Tihan; Seunggu J Han; Margaret R Wrensch; John Wiencke; Michael E Sughrue; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-08-19       Impact factor: 1.961

Review 2.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

3.  Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.

Authors:  Orin Bloch; Michael Lim; Michael E Sughrue; Ricardo J Komotar; John M Abrahams; Donald M O'Rourke; Anthony D'Ambrosio; Jeffrey N Bruce; Andrew T Parsa
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

4.  Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells.

Authors:  Carlos Barcia; Aurora Gómez; José M Gallego-Sanchez; Ana Perez-Vallés; Maria G Castro; Pedro R Lowenstein; Carlos Barcia; Maria-Trinidad Herrero
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

Review 5.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

6.  Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma.

Authors:  Laura R Díaz; Elena Saavedra-López; Leire Romarate; Izaskun Mitxitorena; Paola V Casanova; George P Cribaro; José M Gallego; Ana Pérez-Vallés; Jerónimo Forteza-Vila; Clara Alfaro-Cervello; José M García-Verdugo; Carlos Barcia; Carlos Barcia
Journal:  JCI Insight       Date:  2018-09-20

7.  Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

Authors:  Orin Bloch; Courtney A Crane; Yelena Fuks; Rajwant Kaur; Manish K Aghi; Mitchel S Berger; Nicholas A Butowski; Susan M Chang; Jennifer L Clarke; Michael W McDermott; Michael D Prados; Andrew E Sloan; Jeffrey N Bruce; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

8.  Inherited variation in immune genes and pathways and glioblastoma risk.

Authors:  Judith A Schwartzbaum; Yuanyuan Xiao; Yanhong Liu; Spyros Tsavachidis; Mitchel S Berger; Melissa L Bondy; Jeffrey S Chang; Susan M Chang; Paul A Decker; Bo Ding; Sarah J Hepworth; Richard S Houlston; Fay J Hosking; Robert B Jenkins; Matthew L Kosel; Lucie S McCoy; Patricia A McKinney; Kenneth Muir; Joe S Patoka; Michael Prados; Terri Rice; Lindsay B Robertson; Minouk J Schoemaker; Sanjay Shete; Anthony J Swerdlow; Joe L Wiemels; John K Wiencke; Ping Yang; Margaret R Wrensch
Journal:  Carcinogenesis       Date:  2010-07-28       Impact factor: 4.944

9.  Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.

Authors:  Samik Basu; Tatiana Golovina; Tatiana Mikheeva; Carl H June; James L Riley
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

10.  Dynamics of central and peripheral immunomodulation in a murine glioma model.

Authors:  Benjamin C Kennedy; Lisa M Maier; Randy D'Amico; Christopher E Mandigo; Elizabeth J Fontana; Allen Waziri; Marcela C Assanah; Peter Canoll; Richard C E Anderson; David E Anderson; Jeffrey N Bruce
Journal:  BMC Immunol       Date:  2009-02-18       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.